Investigating the utility of VCAN testing as a biomarker of immunotherapeutic response in future studies is warranted and achievable based on these studies, and identifying more accurate biomarkers in this space could expand therapeutic options and provide clinical benefit to thousands of breast cancer patients. This evidence concerns the gene VCAN and breast cancer.